Pulmonary Embolism

Medically Reviewed by Dr. M. Salar Raza | Official SCFHS 2026 Blueprint

Clinical Pathway

Pulmonary embolism (PE) is a life-threatening condition caused by a blockage in one of the pulmonary arteries in the lungs, most commonly due to a blood clot that has traveled from a deep vein in the legs or pelvis (deep vein thrombosis). This obstruction impedes blood flow to parts of the lung, leading to impaired gas exchange and potential cardiovascular collapse. Acute treatment typically involves prompt anticoagulation with agents such as unfractionated heparin, low molecular weight heparin, or direct oral anticoagulants (DOACs) to prevent clot propagation and new clot formation. In high-risk PE with hemodynamic instability, thrombolysis (fibrinolysis) may be administered to dissolve the clot. Surgical pulmonary embolectomy or catheter-directed interventions are considered for patients with massive PE who cannot receive or have failed thrombolysis. Symptoms are often non-specific and can include sudden onset of dyspnea, pleuritic chest pain (pain on breathing), and cough. Signs may include tachypnea (rapid breathing), tachycardia (rapid heart rate), hypoxemia, and in severe cases, syncope, hypotension, or signs of right heart failure. Hemoptysis (coughing up blood) may also occur.

Clinical Reasoning

A thrombus, typically originating from the deep venous system (e.g., lower extremities), embolizes and travels through the right side of the heart to the pulmonary circulation. The mechanical obstruction of pulmonary arteries leads to an increase in pulmonary vascular resistance and a ventilation-perfusion (V/Q) mismatch, impairing gas exchange. Large emboli can cause acute right ventricular strain and failure, leading to systemic hypotension and cardiogenic shock. The prognosis of pulmonary embolism is highly variable and depends on the size of the embolism, the patient's underlying cardiopulmonary status, and the timeliness of diagnosis and treatment. While many patients recover well with appropriate therapy, massive PE carries a significant mortality risk. Long-term complications can include post-PE syndrome and chronic thromboembolic pulmonary hypertension (CTEPH). Prolonged immobilization (e.g., long flights, bed rest),Recent surgery, particularly orthopedic surgery (hip/knee replacement),Cancer and its treatment,Oral contraceptive use or hormone replacement therapy (HRT),Inherited or acquired thrombophilias (e.g., Factor V Leiden mutation),Previous history of deep vein thrombosis (DVT) or pulmonary embolism (PE)

Sample MCQ

A 28-year-old woman presents with acute-onset dyspnea and pleuritic chest pain. She has no history of connective tissue disease and reports a negative family history for thrombosis. She is subsequently diagnosed with pulmonary embolism. Which of the following is an indication to perform a thrombophilia workup?

  • AAge > 55 years
  • BCurrent oral contraceptive use
  • CHistory of connective tissue disease
  • DNegative family history of thrombosis

Correct Answer: History of connective tissue disease

### TLDR A thrombophilia workup is indicated for patients with venous thromboembolism (VTE) under specific circumstances. A history of connective tissue disease is a strong indication, as these conditions are frequently associated with acquired thrombophilias, such as antiphospholipid syndrome. Other factors like younger age or unprovoked VTE are more relevant than older age. Current oral contraceptive use often represents a provoked event and does not routinely warrant a workup for a first VTE without additional risk factors. A negative family history reduces, rather than increases, the need for a workup. ### Comparison Table | Option | Indication for Thrombophilia Workup? | Reason/Relevance | Key Information | |---|---|---|---| | Age > 55 years | No | Older age generally increases VTE risk due to acquired factors; primary thrombophilias are less often the sole cause. Workup is more relevant for younger patients (<50 years) with unprovoked VTE. | Younger age (<50 years) with unprovoked VTE is a stronger indicator. | | Current oral contraceptive use | No (usually) | Oral contraceptive use is a common, strong provoking factor for VTE. For a first, clearly provoked VTE, thrombophilia testing is generally not recommended unless other risk factors (e.g., strong family history, recurrent events) are present. | Provoked VTE by OCPs typically does not require a workup for a first event. | | **History of connective tissue disease** | **Yes** | **Many connective tissue diseases (e.g., Systemic Lupus Erythematosus) are strongly associated with acquired thrombophilias, particularly antiphospholipid syndrome, which increases thrombosis risk.** | **Connective tissue diseases often point to underlying or acquired thrombophilic states like Antiphospholipid Syndrome.** | | Negative family history of thrombosis | No | A positive family history of VTE, especially early-onset or recurrent events, is an indication. A negative family history reduces the likelihood of a hereditary thrombophilia. | A positive family history is an indication; a negative one is not. | ### Detailed Breakdown Thrombophilia refers to an increased predisposition to thrombosis due to congenital or acquired defects in the coagulation system. Identifying an underlying thrombophilia can influence management, particularly regarding the duration of anticoagulation. **Why a History of Connective Tissue Disease is an Indication:** Connective tissue diseases, such as Systemic Lupus Erythematosus (SLE), are strongly linked to acquired thrombophilia, most notably antiphospholipid syndrome (APS). APS is characterized by the presence of antiphospholipid antibodies that can cause both arterial and venous thrombosis, as well as pregnancy complications. Therefore, if a patient has a history of a connective tissue disease, investigating for associated thrombophilia (e.g., testing for lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2-glycoprotein I antibodies) is appropriate. **Why Other Options Are Not Primary Indications:** * **Age > 55 years:** While VTE risk increases with age, thrombophilia testing is more commonly indicated for younger patients (typically <45-50 years) who experience an unprovoked VTE, as this raises suspicion for an underlying genetic predisposition. In older individuals, VTE is more often attributable to acquired risk factors such as malignancy, immobility, or surgery. * **Current oral contraceptive use:** Oral contraceptives are a well-established provoking factor for VTE. A pulmonary embolism occurring in the setting of oral contraceptive use is generally considered a provoked event. Most guidelines do not recommend routine thrombophilia testing for a first provoked VTE, especially when the provoking factor is clear and reversible, unless there are other compelling reasons such as a strong family history of VTE or recurrent events. * **Negative family history of thrombosis:** A *positive* family history of VTE (especially in first-degree relatives, or involving early-onset or recurrent events) is a significant indicator for considering a thrombophilia workup. Conversely, a negative family history lessens the likelihood of a hereditary thrombophilia and would not, by itself, prompt a workup.

Related Clinical Topics

AIDS

AIDS (Acquired Immunodeficiency Syndrome) is the final, most severe stage of HIV infection, characterized by a profoundly compromised immune system that makes individuals highly susceptible to opportunistic infections and certain cancers. It is diagnosed when the CD4+ T-cell count drops below 200 cells/mm³ or when specific AIDS-defining opportunistic illnesses develop. The cornerstone of AIDS treatment is highly active antiretroviral therapy (HAART), a combination of drugs that suppress HIV replication, preserve immune function, and prevent further progression. HAART significantly reduces viral load, increases CD4+ T-cell counts, and improves overall health. Treatment also includes prophylactic antibiotics to prevent opportunistic infections and specific therapies for any active infections or cancers. Symptoms of AIDS are primarily due to the opportunistic infections and cancers that take advantage of the severely weakened immune system. Common manifestations include persistent fever, chronic diarrhea, significant unintentional weight loss, night sweats, fatigue, swollen lymph nodes, and recurrent severe infections like Pneumocystis pneumonia, Kaposi's sarcoma, and toxoplasmosis. Neurological complications such as AIDS dementia complex can also occur.

Bradycardia

Bradycardia is a medical condition characterized by a slower than normal heart rate, typically defined as fewer than 60 beats per minute (bpm) in adults. While sometimes physiological and benign, it can also indicate underlying cardiovascular or systemic issues that impair the heart's ability to effectively pump blood. Treatment for bradycardia depends on its underlying cause, severity, and the presence of symptoms. Asymptomatic bradycardia, especially in athletes, often requires no intervention. Symptomatic bradycardia may necessitate discontinuing or adjusting causative medications, treating underlying conditions, or in severe cases, implanting a permanent pacemaker to regulate heart rhythm. Acute, unstable bradycardia may require intravenous atropine or temporary pacing. Clinical manifestations range from asymptomatic presentation to severe symptoms depending on the degree of bradycardia and the patient's cardiovascular reserve. Common symptoms include fatigue, dizziness, lightheadedness, syncope (fainting), shortness of breath, and chest pain. In critical cases, it can lead to confusion, hypotension, and signs of organ hypoperfusion.

Chronic Hepatitis C Virus infection

Chronic Hepatitis C Virus (HCV) infection is a persistent inflammatory condition of the liver caused by the hepatitis C virus, defined by the presence of detectable HCV RNA for at least six months. This long-term infection can progressively lead to significant liver damage, including fibrosis, cirrhosis, and hepatocellular carcinoma. Current treatment primarily involves direct-acting antiviral (DAA) medications, which are highly effective oral regimens targeting specific viral proteins to inhibit HCV replication. These therapies typically achieve a sustained virologic response (SVR) in over 95% of patients, effectively curing the infection. Treatment duration usually ranges from 8 to 12 weeks, depending on the specific regimen and patient factors. Chronic HCV infection is often asymptomatic for many years, leading to a silent progression of liver disease. When symptoms do appear, they are often non-specific, such as fatigue, malaise, nausea, and right upper quadrant discomfort. As the disease advances to cirrhosis, signs of liver decompensation may emerge, including jaundice, ascites, peripheral edema, spider angiomata, and hepatic encephalopathy.

SMLE Preparation Resources

Master the 2026 SMLE

Explore more clinical protocols in the SMLEREVISE Clinical Knowledge Library.

Try the QBank & Scaled Mocks